David A. Siegel Oric Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Oric Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 80,100 shares of ORIC stock, worth $796,995. This represents 0.0% of its overall portfolio holdings.
Number of Shares
80,100
Previous 29,100
175.26%
Holding current value
$796,995
Previous $400,000
41.5%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding ORIC
# of Institutions
116Shares Held
63.1MCall Options Held
0Put Options Held
0-
Nextech Invest Ag5.29MShares$52.6 Million7.05% of portfolio
-
Black Rock Inc. New York, NY4.83MShares$48.1 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY4.39MShares$43.7 Million3.41% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA4.14MShares$41.2 Million1.73% of portfolio
-
Viking Global Investors LP4MShares$39.8 Million0.11% of portfolio
About Oric Pharmaceuticals, Inc.
- Ticker ORIC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,576,700
- Market Cap $394M
- Description
- ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...